ICONIC: Carpediem Outcomes in Infants Through Collaboration

Sponsor
Children's Hospital Medical Center, Cincinnati (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05161078
Collaborator
(none)
1,000
1
96.5
10.4

Study Details

Study Description

Brief Summary

To date, little knowledge exists related to the use of hemodialysis (HD) in infants and has been limited to mainly single center studies. The CARPEDIEM (CArdio-Renal PEdiatric Dialysis Emergency Machine) device, which can be used to provide hemodialysis in infants, has been launched in the United States. This study/registry is designed to obtain data on critically ill infants who require HD using the CARPEDIEM device to understand the indications for initiation, best practice in prescribing and performing treatment, expected treatment course, and outcomes of a dedicated infant continuous renal replacement therapy (CRRT) machine.

Condition or Disease Intervention/Treatment Phase
  • Device: CARPEDIEM

Detailed Description

This is a retrospective and prospective, multicenter observational quality improvement study and research registry. Infants undergoing renal replacement therapy utilizing CARPEDIEM for hemodialysis will be enrolled in the study for observation. There are two arms to this study, one for quality improvement and one for research purposes. Patients enrolled in this study have the option to participate additionally in either biospecimen collection, long term follow up after CARPEDIEM, or both. Urine specimen will be collected from fresh voids, but all blood specimen will be obtained from residual clinical specimen. Investigators hope to gain more information into use, treatment course, and outcomes from infants requiring treatment with the CARPEDIEM device.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
1000 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
Improving Carpediem Outcomes in Neonates and Infants Through Collaboration
Actual Study Start Date :
Dec 16, 2021
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Dec 31, 2029

Arms and Interventions

Arm Intervention/Treatment
All Patients Enrolled

Patients will be treated with CARPEDIEM per standard of care.

Device: CARPEDIEM
CARPEDIEM treatment as per local standard of care

Outcome Measures

Primary Outcome Measures

  1. Number of CARPEDIEM filters to meet prescribed treatment length [24 hours]

    Comparing actual time of treatment of each CARPEDIEM filter to the initial prescribed length of treatment at the time of filter initiation

  2. Rate of patient survival [through hospital discharge, an average of less than 1 year]

    Percent of patients treated with the CARPEDIEM who survive to hospital discharge

  3. Rate of renal recovery [through hospital discharge, an average of less than 1 year]

    Excluding patients with End Stage Renal Disease (ESRD), percent of patients treated with the CARPEDIEM who recover baseline renal function as measured by liberation from dialysis and serum creatinine returning to within less than a 50% increase over baseline.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Treated with CARPEDIEM as part of standard of care at a participating institution within the United States
Exclusion Criteria:
  • Parents/legally authorized representative unable or unwilling to provide consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cincinnati Children's Hospital Medical Center Cincinnati Ohio United States 45229

Sponsors and Collaborators

  • Children's Hospital Medical Center, Cincinnati

Investigators

  • Principal Investigator: Cara Slagle, MD, Cincinnati Children's

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Children's Hospital Medical Center, Cincinnati
ClinicalTrials.gov Identifier:
NCT05161078
Other Study ID Numbers:
  • CIN001 - ICONIC
First Posted:
Dec 16, 2021
Last Update Posted:
Feb 23, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 23, 2022